- Conditions
- Geographic Atrophy
- Interventions
- Vonaprument
- Drug
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • St. Petersburg, Florida • Hagerstown, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Cystoid Macular Edema,, Retinal Thickening
- Interventions
- 2. Xibrom (Bromfenac), 1. Pred Forte
- Drug
- Lead sponsor
- Center For Excellence In Eye Care
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
- Interventions
- Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
- Combination Product
- Lead sponsor
- MediBeacon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Macular Degeneration
- Interventions
- pazopanib, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
- Interventions
- nGoggle
- Device
- Lead sponsor
- NGoggle
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 200 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Exudative Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Exudative Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- Doxycycline Hyclate, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
- Interventions
- Ranibizumab, No Ranibizumab
- Drug · Other
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Geographic Atrophy (GA)
- Interventions
- Pozelimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • East Weymouth, Massachusetts • Austin, Texas + 2 more
- Conditions
- Hippel-Lindau Disease
- Interventions
- EYE001
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina + 1 more
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Ranibizumab (Lucentis), Argon Laser
- Drug · Procedure
- Lead sponsor
- Rocky Mountain Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- Faricimab PFS Configuration
- Combination Product
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Mesa, Arizona • Phoenix, Arizona
- Conditions
- Diabetic Macular Edema
- Interventions
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Macular Edema, Diabetes Mellitus
- Interventions
- Dexamethasone intravitreal implant, Steroid plus NSAID eye drop combination therapy
- Drug
- Lead sponsor
- Retinal Consultants of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Tissue Plasminogen Activator
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- EYP-1901
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Intravitreal aflibercept injection, Placebo
- Drug
- Lead sponsor
- Jeffrey S Heier
- Other
- Eligibility
- Not listed
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Avacincaptad Pegol, Lucentis
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
- Device · Drug
- Lead sponsor
- Retina Macula Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Torrance, California